News
Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...
23h
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...
A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health issues like dementia ...
Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.
18h
DPA International on MSNWeight loss jabs linked to lower dementia and stroke riskWeight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...
PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...
Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results